Ultime notizie per Baosheng Media Gr (NASDAQ:BAOS) Azioni

Baosheng Media Gr

Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original big data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.

Baosheng Media Group Holdings Limited - Ordinary shares

Baosheng Media Group Holdings Ltd

Barclays analyst Julian Mitchell maintains APi Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) with a Overweight and raises the price target from $43 to $44.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on APi Gr, Raises Price Target to $44

KITT

Nauticus Robotics Secures Agreement To Convert $33M Debt Into Equity Via Preferred Stock Exchange, Aiming To Deleverage Balance Sheet And Address Nasdaq Compliance

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Ceva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) is &#8220;way too high, and I think you <a href="https://www.benzinga.com/quote/CEVA">should take something off the table.&#8221;</a>
Ceva will announce results for the third quarter on Nov. 7, 2024, before the opening bell.
&#8220;I love space stuff, and that's why I keep recommending Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>),&#8221; Cramer said when asked about Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>). If there's going to be something in space, it is going to be done by Elon Musk."
Intuitive Machines will release its financial results for the third quarter on Thursday, Nov. 14, before the market opens.
When asked about Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), &#8220;I want so badly for the company to do well, but I can't recommend the stock.&#8221;
The company is reportedly set to pause production of its F-150 Lightning from mid-November until the year&#8217;s end, citing weaker-than-anticipated demand for the electric pickup, Automotive News reported.
&#8220;They are in the oil service business, and oil is not a growth commodity. So, I'm going to say you can't own the stock here, as much as I really like them,&#8221; the &#8220;Mad Money&#8221; host said when asked about SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
The company, last week, disclosed that its OneSubsea joint venture won a contract from BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) for a subsea boosting system as part of the greenfield development of the Kaskida project in the deepwater U.S.
Cramer recommended taking something off the table, when asked about Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>).
Vistra will replace The AES Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) in the Dow Jones Utility Average, effective prior to the open of trading on Friday, Nov. 8.
Price Action:
<ul>
<li>CEVA shares fell 0.2% to settle at $23.64 on Monday.</li>
<li>Intuitive Machines shares fell 6.5% to close at $7.58 on Monday.</li>
<li>Ford shares gained 1.4% to settle at $10.36 during the session.</li>
<li>SLB gained 1.4% to settle at $40.32 on Monday.</li>
<li>Vistra shares fell 3.2% to close at $115.74.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>

Long Ideas

Markets

Media

CEVA

LUNR

TSLA

Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'

WIIM

DuPont shares are trading higher after the company reported better-than-expected Q3 EPS and raised its FY24 adjusted EPS guidance.

APLS

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 5.04% since its last report. The company recently reported that it has 70.94 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Pfizer's Recent Short Interest

KKR's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) short percent of float has fallen 13.57% since its last report. The company recently reported that it has 11.63 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KKR Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KKR has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing KKR's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KKR's peer group average for short interest as a percentage of float is 3.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into KKR's Recent Short Interest

PDD Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NYSE">PDD</a>) short percent of float has fallen 7.83% since its last report. The company recently reported that it has 32.98 million shares sold short, which is 4.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PDD Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814314_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PDD Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PDD Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PDD Holdings's peer group average for short interest as a percentage of float is 9.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Looking Into PDD Holdings's Recent Short Interest

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $18 to $14.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $14

AHCO

AdaptHealth Corp shares are trading lower after the company reported worse-than-expected Q3 sales and revised its FY24 net revenue guidance

Cleveland-Cliffs shares are trading lower following worse-than-expected Q3 financial results.

LSCC

Lattice Semiconductor shares are trading lower following soft Q4 guidance.

Mission Produce shares are trading higher after the company raised its Q4 guidance above estimates.

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Equal-Weight and raises the price target from $7 to $8.

BCRX

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $8

Barclays analyst Ryan Macwilliams maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Equal-Weight and raises the price target from $2 to $2.5.

EGHT

Barclays Maintains Equal-Weight on 8x8, Raises Price Target to $2.5

SKYT

SkyWater Technologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $9 to $12.

LUMN

Lumen Highlights Use Of Google Cloud For AI Services

Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.44) by 11.36 percent. This is a 34.48 percent decrease over losses of $(0.29) per share from the same period last year.

Earnings

Earnings Beats

INZY

Inozyme Pharma Q3 EPS $(0.39) Beats $(0.44) Estimate

Veru Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
Highlights from the presentation: The objective of the meta-analysis was to determine the effects of enobosarm on body composition in older patients that had obesity who were enrolled in 4 previously conducted randomized clinical trials of enobosarm that measured body composition including Phase 2 older males and postmenopausal women, Phase 2 advanced cancer patients with muscle wasting, and two Phase 3 advanced lung cancer patients with cancer wasting.
Meta-analysis was conducted in older (≥60 years old) subjects with obesity (BMI ≥30), treated with enobosarm 3mg per day versus placebo, and who had a Day 84 (n= 60) and Day 147 (n=45) DEXA scans to assess body composition.
Results of DEXA scan assessments of body composition in older subjects with obesity: At Day 84, enobosarm 3mg treatment compared to placebo resulted in an absolute increase in lean mass (0.05 kg enobosarm vs -1.54 kg placebo) and absolute decrease in fat mass (-1.48 kg enobosarm vs placebo -0.35 kg).
At Day 147, enobosarm 3mg treatment compared to placebo resulted an absolute increase in lean mass (-0.79 kg enobosarm vs -1.77 kg placebo) and absolute decrease in fat mass (-2.05 kg enobosarm vs -0.05 kg placebo).
At Day 147, enobosarm 3mg treated subjects compared to placebo had greater total weight loss by DEXA scan (-2.93 kg for enobosarm and -2.11 kg for placebo).
Enobosarm was generally well-tolerated with no increase in gastrointestinal side effects.

Biotech

General

VERU

Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek

IMAX, CPOP among major communication services gainers; IAS, SSP among losers

The market has been high on Baosheng Media Group Holdings Ltd (BAOS)  stock recently. BAOS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Baosheng Media Group Holdings Ltd has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BAOS!See Full BAOS ReportW

Should You Buy Baosheng Media Group Holdings Ltd (BAOS) Stock on Thursday?

Baosheng Media Group Holdings Ltd (BAOS) has released an update. Baosheng Media Group Holdings Ltd is facing a lawsuit from three institutional inv...

Baosheng Media Confronts Investor Lawsuit

PARA, AMC among major communication services gainers; NFLX, TC among losers

Baosheng Media Group Holdings Ltd (BAOS) has released an update. Baosheng Media Group Holdings Ltd is currently facing a legal challenge as Orient ...

Baosheng Media Confronts Shareholder Lawsuit

Baosheng Media Group Holdings Ltd (BAOS) has released an update. Baosheng Media Group Holdings Ltd faces a significant legal challenge as a petitio...

Baosheng Media Grapples with Liquidation Petition

CMCM, BZFD among major communication services gainers; MDIA, IHRT among losers

KUKE, FENG among major communication services gainers; CCG, MSGM among losers

Baosheng Media Group Holdings (BAOS) has released an update. Baosheng Media Group Holdings Limited has faced the termination of two significant inv...

Baosheng Media Faces Investment Deal Terminations

Baosheng Media Group Holdings (BAOS) has released an update. Baosheng Media Group Holdings reports a net loss of $1,740,418 for the six months ende...

Baosheng Media Reports Increased Half-Year Loss

BAOS

BZFD

CMCM

CMLS

CPOP

CURI

DLPN

FENG

GSAT

IHRT

IMAX

KUKE

MCHX

MDIA

MSGM

NFLX

PARA

PGRU

UONE

WIMI

Opinion

Press Releases

Thinking about buying stock in WeTrade Group, Nio, Arista Networks, Baosheng Media, or TAL Education Group?

Baosheng Media Group Holdings Limited Announces Filing of Current Report on Form 6-K with the SEC regarding Pending Legal Proceeding

ANET

WETG

AirNet Technology Inc. - American Depositary Shares, each representing one ordinary shares

Comments

Baosheng Media Gr

Notizie

Ultime notizie per Baosheng Media Gr (NASDAQ:BAOS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO